Richard M. Stone, MD, Chief of Staff, Director, Translational Research, Leukemia Division, Medical Oncology, Dana-Farber Cancer Institute, and Professor of Medicine, Harvard Medical School, Boston, Massachusetts,recently shared updates on the treatment of high-risk acute myeloid leukemia (AML) at Miami Cancer Institutes Second Summit of the Americas on Immunotherapies for Hematologic Malignancies.
Dr Stone said he typically divides patients with AML into good risk, intermediate risk, and high-risk, by focusing on gene fusion and certain mutations. High-risk AML typically includes patients with wild-type NPM1 and high FLT3-ITD ratio; inv(3); t(6;9) abnormalities of MLL rearrangements; and complex karyotypes, he said.
I think high risk AML really is almost every patient with AML, because only about 15% have what we would consider favorable risk, Dr Stone said.
According to him, AML patients with complex karyotypes do worse than those with TP53 mutations that do not have a complex karyotype.
Obviously, P53 mutations are the absolute worst, he added.
One way to treat high-risk AML, including those with therapy-related histories, history of mild-dysplasia beforehand, or mild-dysplasia related chromosomal abnormality, is to use CPX-351, a liposomal co-formulation of cytarabine and daunorubicin designed to achieve synergistic antileukemia activity.
These liposomes stick around the bone marrow for a while, which could account for the efficacy of this drug, Dr Stone said.
Referring to a randomized Phase 3 trial of CPX-351 versus 7+3 in older patients with secondary AML, Dr Stone said CPX-351 is better than 7+3 in patients between 60 and 75 years of age who have a history of prior bone problems.
The median survival in this trial was superior in the CPX-351 group (9.56) than the 7+3 group (5.95). Also, those who had a transplant after having received CPX-351 fared much better than those who had transplant after having 7+3, Dr Stone said.
Perhaps, due to the fact that CPX-351 led to remissions at a lower level disease burden, Dr Stone said.
On the topic of FLT3 AML, Dr Stone said patients can benefit from the addition of midostaurin, which, based on a recent trial, showed significant improvement in survival.
In an effort to improve upon midostaurin as a FLT3 inhibitor by adding gilteritinib to chemotherapy, Dr Stone said there are a number of randomized trials comparing gilteritinib plus chemotherapy to midostaurin plus chemotherapy, and prenolin plus chemotherapy to midostaurin plus chemotherapy.
The treatments may also be improved upon by adding BCL-2 inhibitor venetoclax, Dr Stone said, noting a phase 1 study on the maximal tolerated dose of venetoclax in combination with daunorubicin/cytarabine induction in previously untreated adults with AML. The complete response (CR) rate for the first 13 patients was 11/13. Of the 11 CRs, minimal residual disease (MRD) was measured by flow cytometry in 9. Seven of 9 were MRD negative at CR.
Looking at uncontrolled data of azacitidine and venetoclax, and decitabine and venetoclax, in AML patients who were not deemed fit for chemotherapy, there was a much higher response rate among all genetic subtypes than what would be expected with azacitidine and venetoclax or azacitidine alone, Dr Stone said.
The VIALE-A randomized trial, published last summer by Dr Courtney DiNardo and colleagues, compared venetoclax and azacitidine to placebo and azacitidine in patients that were either 75 years of age or older, or between 18-74 years of age with at least 1 significant comorbidity, such as CHF. This trial showed that there was a significant improvement in survival for patients who received venetoclax rather than placebo, with a nice reduction in the hazard ratio (HR 0.66, 95% CI, 0.52-0.85, P=.001) indicating better outcomes with azacitidine and venetoclax.
However, Dr Stone said, not all patients benefitted equally from the combination compared to azacitidine alone. Those patients were under 75 years of age with significant comorbidities, and did not benefit that much from adding venetoclax to azacitidine. But, almost all genetic subtypes did, especially those with the molecular markers IDH1 and IDH2.
Looking at oral azacitidine in the post-remission setting, Dr Stone said it causes a number of biochemical changes in the cell including DNA hypomethylation, DNA damage and RNA disruption.
The QUAZAR AML-001 study took patients who were 55 or older who got intensive chemotherapy with either 1 or 2 cycles of the consolidation, but were not going to have a stem cell transplant; have intermediate- or poor-risk cytogenetics; and were not candidates for HSCT. Patients either received placebo (n=234) for 14 days or oral azacitidine (n=238) for 14 days every month, and kept receiving it until they relapsed.
Patients who were randomized to receive the oral azacitidine enjoyed a superior overall and relapse-free survival. So, that was quite exciting. The problem is how many patients are there who are 55 or greater who get intensive chemotherapy, but who arent going to get the stem cell transplant. Nonetheless, this is a very important study, Dr Stone said.
Dr Stone finished up with relapsed AML. The treatment goal in general, he said, is to induce the second remission then perform an allogeneic stem cell transplant.
There are a variety of new treatment options for relapsed AML, including enasidenib for the IDH2 mutation, ivosidenib for IDH1, and gilteritinib for FLT3.
There are a lot of new ideas, but in the phase 3 ADMIRAL trial for R/R mutant FLT3 AML, gilteritinib beat salvage chemotherapy in the post-remission setting leading to superior median overall survival, Dr Stone said. However, when adding venetoclax to gilteritinib, there is a very impressive response rate, although theres a lot of mild suppression. The response rate was quite high (86%, n=41) overall, as well as in the prior FTL3 TKI exposure group (82%, n = 28). Although the median survival was relatively short, the survival appears to be good for those with the ITD subtype of FLT3.
In terms of venetoclax in combination with FLAG-IDA in R/R AML, Dr Stone mentioned a Phase 1b/2 trial led by Dr DiNardo on venetoclax in combination with AML induction/consolidation therapy with FLAG-IDA in patients with newly diagnosed R/R AML.
Dr Stone said what needed to be done was decrease venetoclax from the original 21-day dosing to 14 days as well as regulate cytarabine from 2 gm/m2 to 1.5gm/m2. The overall response rate in this trial was good (82%, n = 56), he said. There was high composite CR (76%, n = 52) as well. Overall, survival was good with some drop off in the R/R patient. However, mutated FLT3-AML did not do as well.
The problem of what to do with mutant FLT3 AML in the upfront and relapse setting remains an unanswered question.
Dr Stone said he hopes certain molecules will afford help for FLT3 AML, such as APR-246, a so-called p53 refolding agent; anti-CD47 antibody (5F9); or anti-CD70 antibody. In turn, Dr Stone referenced a Phase 1b study showing how effective the anti-CD47 antibody magrolimab combined with azacitidine is in AML patients.
The trial provided patients with a magrolimab priming dose of 1mg/kg, necessary, Dr Stone said, because of the expression of CD47 on the surface of red cells, and a dose ramp-up was utilized to mitigate on-target anemia. Most patients received magrolimab 30 mg/kg weekly or every other week along with a standard dose of azacitidine. The ORR was good (63%, n = 27) as well as the CR rate (42%, n = 18), with similar responses in TP53-mutant patients. In all, magrolimab plus azacitidine efficacy compared favorably to azacitidine monotherapy (CR rate 18-20%). The median OS was 18.9 months in TP53 wild-type patients and 12.9 months in the TP53-mutant patients.
This is a very promising combination, he said.
In conclusion, Dr Stone said, most patients with AML are high-risk. However, there are new treatment options for inductions, including CPX-351, midostaurin, and azacitidine/venetoclax; maintenance, including oral azacitidine; and relapse, including gilteritinib. There are also a number of new combinations on the way, including venetoclax and gilteritinib, he said.Emily Bader
Read the original here:
Richard Stone, MD, on Updates in the Treatment of High-Risk AML - Oncology Learning Network
- The ISSCR announces 2024 election results - EurekAlert - March 28th, 2024
- Exosomes and Stem Cells Are the Future of Anti-Aging - NewBeauty Magazine - March 28th, 2024
- Charles River Extends Gene Therapy Alliance with NUS Medicine - Contract Pharma - March 22nd, 2024
- Exciting opportunities in stem cell technology and regenerative biology in Indian healthcare industry - Express Healthcare - March 22nd, 2024
- Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine - Yahoo Finance - March 22nd, 2024
- Opinion: The revolutionary sickle cell therapies - MSN - March 22nd, 2024
- 10 Years of Kansas Regenerative Medicine Center - KSAL - March 22nd, 2024
- BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership - Diagnostic and Interventional Cardiology - March 17th, 2024
- Cynata Therapeutics' breakthrough in regenerative medicine - Finance News Network - March 17th, 2024
- New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia - GlobeNewswire - March 17th, 2024
- Novel 3D stem cell therapy to treat critical limb ischaemia - Drug Target Review - March 15th, 2024
- Breaking Boundaries: Pharmicell's Bold Vision for Healthcare Transformation and Monumental Growth - The Worldfolio - March 15th, 2024
- CuSTOM Organoid Research Evolving From Tool to Treatment - Research Horizons - Research Horizons - March 15th, 2024
- BioCardia and StemCardia Announce Partnership to Deliver Cell-Gene Therapy for Remuscularization of Heart - Cath Lab Digest - March 15th, 2024
- Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine ... - Business Wire - March 13th, 2024
- Iron restriction keeps blood stem cells young, researchers find - Phys.org - March 13th, 2024
- Vitamin A could have a key role in both stem cell biology and wound healing: Study - Medical Dialogues - March 9th, 2024
- Trends in Stem Cell Transplantation Refusal for Myeloma Treatment - Targeted Oncology - March 7th, 2024
- Stem Cell Therapy Market (CAGR) of 31.1%, Future of Market Size Emerging Technologies and their Impact on ... - Taiwan News - March 7th, 2024
- This Swedish startup wants to reduce the cost, and controversy, around stem cell production - TechCrunch - March 6th, 2024
- Advancing stem cell therapy: The regulatory process to get to clinical trials - The Economic Times - March 6th, 2024
- Transitioning from traditional surgical methods to the innovative use of stem cells - pharmaphorum - March 6th, 2024
- 'Mini organs' are grown from human stem cells taken during the late stages of pregnancy for the first time - m - Daily Mail - March 6th, 2024
- Stem cell transplant cures man of HIV and leukemia, one of five to achieve full remission - Fox 28 - March 3rd, 2024
- Stem Cell Therapy Market to Boost USD 137.5 Billion by 2034 and Projected to grow at 32.10% CAGR with increasing ... - Yahoo Finance - March 1st, 2024
- Studies expand use of stem cell therapies - WPLG Local 10 - March 1st, 2024
- Innovative therapy targets and destroys leukemia stem cells - News-Medical.Net - February 27th, 2024
- Unlocking the Potential of Stem Cells: The Medical Revolution of the Century - EIN News - February 27th, 2024
- Pelage Pharmaceuticals Announces $16.75M Series A Financing led by GV to Revolutionize Regenerative Medicine ... - Yahoo Finance - February 27th, 2024
- Say Her Name - Henrietta Lacks, The Real Mother Of Stem - Her Campus - February 27th, 2024
- California Man Free of HIV And Cancer in Astonishing Medical Recovery - ScienceAlert - February 25th, 2024
- $93 million for research into improved health for children, young people and the aged, medical devices, mental health ... - Department of Health - February 25th, 2024
- Stem Cells in Regenerative Medicine - PMC - National Center for ... - February 24th, 2024
- The Promise and Reality of Stem Cell Therapy: What You Need to Know - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy: A Beacon of Hope for Patients with Untreatable Conditions - Corporate Wellness Magazine - February 22nd, 2024
- Leading Experts in Stem Cell Therapy: A Global Overview - Corporate Wellness Magazine - February 22nd, 2024
- Can Stem Cells Help Reverse the Effects of Aging? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy for Cancer: Hope on the Horizon? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cells and Autism: A Closer Look at Innovative Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Regrowth and Restoration: The Science Behind Stem Cell Therapy for Hair - Corporate Wellness Magazine - February 22nd, 2024
- Brain Recovery: The Role of Stem Cells in Stroke and Cerebral Palsy Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Turning Back the Clock: The Science of Stem Cells in Anti-Aging - Corporate Wellness Magazine - February 22nd, 2024
- Insights into cellular therapies for cancer treatment - Drug Target Review - February 22nd, 2024
- The Role of Stem Cells in Rheumatoid Arthritis Recovery - Corporate Wellness Magazine - February 22nd, 2024
- Dr Ernesto Romeros vision transforms immunotherapy regenerative medicine into a global leader in stem cell treatment - Khaleej Times - February 22nd, 2024
- World-Renowned Doctors Leading the Way in Stem Cell Research and Treatment - Medical Tourism Magazine - February 20th, 2024
- Choosing the Best: A Guide to America's Premier Stem Cell Therapy Providers - Medical Tourism Magazine - February 20th, 2024
- Navigating Through the Possibilities of Stem Cell Treatment for Eye Disorders - Medical Tourism Magazine - February 20th, 2024
- Global Leaders in Stem Cell Therapy: Where Excellence Meets Innovation - Medical Tourism Magazine - February 20th, 2024
- Excellence in Stem Cell Treatment: How the US is Pioneering Global Healthcare Solutions - Medical Tourism Magazine - February 20th, 2024
- Clarifying Memory Loss Treatments: The Role of Stem Cells - Medical Tourism Magazine - February 20th, 2024
- Battling Inflammation: Stem Cell Therapy for Rheumatoid Arthritis - Medical Tourism Magazine - February 20th, 2024
- Digestive Health and Stem Cells: Treating Ulcerative Colitis and Crohn's Disease - Medical Tourism Magazine - February 20th, 2024
- Top Stem Cell Clinics in the USA: Pioneering Treatments for Chronic Conditions - Medical Tourism Magazine - February 20th, 2024
- Stem Cells and Autism: Understanding the Potential for Innovative Treatments - Medical Tourism Magazine - February 20th, 2024
- Stopping the awakening of sleeping Acute Myeloid Leukaemia stem cells to prevent disease relapse - University of Birmingham - February 20th, 2024
- City of Hope Achieves Ground Breaking Treatment for Blood Cancer and HIV - Medriva - February 18th, 2024
- Regenerative Medicine Market Size to Worth USD 95 Billion by 2032 - InvestorsObserver - February 18th, 2024
- North America Organoids Market Projected to Reach US$ 5.35 Billion by 2030, Riding on a CAGR of 21.5% - GlobeNewswire - February 18th, 2024
- Chinese team tests lung treatment that may be first to reverse COPD damage - South China Morning Post - February 15th, 2024
- Why leukemic stem cells not harmed by chemotherapy begin to grow and produce AML cells after treatment - Medical Xpress - February 15th, 2024
- Regenerative Medicine Market is Expected to Reach $49.0 Billion | MarketsandMarkets - Yahoo Finance - February 15th, 2024
- Study finds interleukin-24 enhances CAR-T cell therapy's effectiveness against cancer stem cells - News-Medical.Net - February 15th, 2024
- Oldest Patient 'Cured' of HIV Still in Remission 5 Years After Transplant for AML - Medpage Today - February 15th, 2024
- Drug used for cocaine addiction may pave way for new treatment of advanced colon cancer - EurekAlert - February 15th, 2024
- Hematopoietic Stem Cells and Their Role in Development and Disease Therapy - The Scientist - February 15th, 2024
- Biomedical Researcher Seeks to Improve Outcomes in Stem Cell Treatments - University of Arkansas Newswire - February 13th, 2024
- Top 3 grants in regenerative medicine: January 2024 - RegMedNet - February 13th, 2024
- Scalise returning to Washington next week with cancer in complete remission - The Hill - February 13th, 2024
- Unlocking the power of stem cell therapy - Drug Target Review - February 9th, 2024
- Digging into the Dangers of Gene Therapy - The Medicine Maker - February 7th, 2024
- Treating and preventing abnormal heart beats with stem cell muscle grafts - Medical Xpress - February 7th, 2024
- Regeneration of the Retina Using Pluripotent Stem Cells: A Comprehensive Review - Cureus - February 3rd, 2024
- I thought I'll give it a chance - Liam Harrison reveals his thought process in getting crucial stem cell treatment - Sportskeeda - February 3rd, 2024
- Jennifer J. Raab named President and CEO of The New York Stem Cell Foundation - EurekAlert - February 3rd, 2024
- High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary ... - The Lancet - January 31st, 2024
- Houston regenerative medicine company to IPO, move toward more human trials - InnovationMap - January 31st, 2024
- New study on promising stem cell-based therapy for Crohn's disease - Medical Xpress - January 31st, 2024
- Exploring pharmacological, non-pharmacological, and stem cell therapies for treatment of autism spectrum disorders - News-Medical.Net - January 29th, 2024
- Stem cell study shows how gene activity modulates the amount of immune cell production in mice - Medical Xpress - January 26th, 2024
Recent Comments